Impel Pharmaceuticals refers that the U.S. migraine market is forecast to grow at a compound annual growth rate of 9.9%, reaching $12 billion by 2030, with the introduction of multiple new product offerings and an expected increase in awareness and diagnosis of the disease.
The State of America’s Health Study, 1990-2016 ranks migraine as the fifth leading cause of years lived with disability in 2016.
According to market research commissioned by Impel Pharmaceuticals, approximately 31 million people in the United States suffer migraine attacks.
Most patients experience migraine attacks once or twice a month and more than 1.2 million emergency room visits per year are for acute treatment of migraine attacks.
In addition, with approvals of monoclonal antibodies against calcitonin gene-related peptide for migraine prevention and approvals of new therapies for acute treatment of migraine, such as oral gepants and lasmiditan, increased awareness of migraine and its impact is expected.
Of the approximately 18 million diagnosed migraine patients, some 12 million are not on active treatment.
Of the six million patients diagnosed and on prescribed treatment, up to 79% of patients are willing to try another medication for acute migraine treatment.
Migraine market
According to AEON Biopharma, migraine is a complex neurological condition characterized by recurrent episodes of headache.
Migraine sufferers experience symptoms such as recurrent throbbing pain, nausea, vomiting, dizziness, and sensitivity to light, sound, touch and smell.
Migraine attacks usually last between four and 72 hours.
According to the Global Burden of Disease Study conducted in 2019, migraine is the second leading disability in the world.
The development and course of migraine differs from patient to patient, where a subset of patients experience increased frequency over a period of months or years and may gradually evolve from low-frequency episodic migraine to high-frequency episodic migraine and then to chronic migraine.
According to the MSD manual, onset most often occurs during puberty or in young adults, with ups and downs in frequency and severity over subsequent years and a common decline by age 50. Studies show a familial aggregation of migraine.
An estimated 1 billion people worldwide suffer from migraines, making migraine the third most prevalent disease in the world.
Migraines are a common and debilitating neurological disorder suffered by approximately 4% to 9% of men and 11% to 25% of women, according to the American Headache Society.
